Tag Archives: MHRA

Pharmaceutical Scandal in Britain Sheds Disturbing New Light on Benzodiazepines

Touted as the world’s first wonder drug, benzodiazepines—”benzos” for short—were widely prescribed in the 1960s for anxiety and stress. Within a decade they had become the most commonly used treatment for such conditions in the States and Britain. Use of benzos such as Valium, Mogadon, and Librium in both countries was widespread. Today, the same class of drugs—including Klonopin, Xanax, and Ativan—is still frequently prescribed for anxiety and panic. Widely known to be addictive and to cause a range of serious side effects, benzos became less popular in the 1980s and 1990s owing largely to the rise of SSRI antidepressants, which were widely considered to be safer and nonaddictive. A combined search for benzos and “adverse effects” on PubMed yields a staggering 15,157 hits, ranging from sleep disorders and increased violence among patients to discontinuation problems and dependency issues that bear all the hallmarks of a serious addiction.

UK Drug Regulatory Agency issues warning about potential birth defects from Prozac

The Medicines and Healthcare Products Regulatory Agency (MHRA), the government agency in the UK responsible for medicines and medical devices, has issued a warning about potential SSRI birth defects related to the use of fluoxetine (Prozac). The MHRA issued the warning in its monthly drug safety update. The agency warns that there is a small risk of congenital cardiac defects in infants of mothers who took fluoxetine during the first trimester of pregnancy.